Anyone knows the Gt20029 approx release date? 5/11/2024
A user with stage 1 hair loss is inquiring about the release date of GT20029, hoping to use it instead of Minoxidil and finasteride, as they believe it has better results. They want to know if it will be available in the next couple of years.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
community Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community Is there any new drug that looks promising ?
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
Related Research
6 / 6 resultsresearch Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
This randomized trial found that topical GT20029 significantly increased hair counts and width in Chinese men with androgenetic alopecia over 12 weeks, showing better results than placebo, with the 0.5% once daily and 1.0% twice weekly doses particularly effective.
research Updates in Treatment for Androgenetic Alopecia
This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
research Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.
research Topical solutions for androgenetic alopecia: evaluating efficacy and safety
This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.
research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis
This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.
research Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.